185 related articles for article (PubMed ID: 29724031)
21. NOTCH1 pathway: a molecular target in T-cell cancers?
Holowiecki J
Lancet; 2005 Jan 15-21; 365(9455):197-9. PubMed ID: 15652588
[No Abstract] [Full Text] [Related]
22. Targeting complexes of super-enhancers is a promising strategy for cancer therapy.
Zheng C; Liu M; Fan H
Oncol Lett; 2020 Sep; 20(3):2557-2566. PubMed ID: 32782573
[TBL] [Abstract][Full Text] [Related]
23. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
[TBL] [Abstract][Full Text] [Related]
24. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
25. Growth inhibition of Tax-activated human Jurkat leukemia T cells by all-trans retinoic acid requires JNK-1 inhibition.
Parra E; Gutiérrez L
Oncol Rep; 2013 Jan; 29(1):387-93. PubMed ID: 23129057
[TBL] [Abstract][Full Text] [Related]
26. Targeting BET bromodomains for cancer treatment.
Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
[TBL] [Abstract][Full Text] [Related]
27. Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.
Allen BK; Mehta S; Ember SW; Schonbrunn E; Ayad N; Schürer SC
Sci Rep; 2015 Nov; 5():16924. PubMed ID: 26596901
[TBL] [Abstract][Full Text] [Related]
28. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.
Sun Z; Zhang H; Chen Z; Xie Y; Jiang H; Chen L; Ding H; Zhang Y; Jiang H; Zheng M; Luo C
Bioorg Med Chem Lett; 2017 May; 27(9):2003-2009. PubMed ID: 28347667
[TBL] [Abstract][Full Text] [Related]
29. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
30. Co-overexpression of BRD4 and CDK7 promotes cell proliferation and predicts poor prognosis in HCC.
Li X; Zheng C; Liu Y; Sun H; Qian Y; Fan H
Heliyon; 2024 Jan; 10(2):e24389. PubMed ID: 38293462
[TBL] [Abstract][Full Text] [Related]
31. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.
Brägelmann J; Dammert MA; Dietlein F; Heuckmann JM; Choidas A; Böhm S; Richters A; Basu D; Tischler V; Lorenz C; Habenberger P; Fang Z; Ortiz-Cuaran S; Leenders F; Eickhoff J; Koch U; Getlik M; Termathe M; Sallouh M; Greff Z; Varga Z; Balke-Want H; French CA; Peifer M; Reinhardt HC; Örfi L; Kéri G; Ansén S; Heukamp LC; Büttner R; Rauh D; Klebl BM; Thomas RK; Sos ML
Cell Rep; 2017 Sep; 20(12):2833-2845. PubMed ID: 28930680
[TBL] [Abstract][Full Text] [Related]
32. A20 targets caspase-8 and FADD to protect HTLV-I-infected cells.
Saitoh Y; Hamano A; Mochida K; Kakeya A; Uno M; Tsuruyama E; Ichikawa H; Tokunaga F; Utsunomiya A; Watanabe T; Yamaoka S
Leukemia; 2016 Mar; 30(3):716-27. PubMed ID: 26437781
[TBL] [Abstract][Full Text] [Related]
33. Targeting Transcription Factors for Cancer Treatment.
Lambert M; Jambon S; Depauw S; David-Cordonnier MH
Molecules; 2018 Jun; 23(6):. PubMed ID: 29921764
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
35. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
36. Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells.
Tomita M; Kawakami H; Uchihara JN; Okudaira T; Masuda M; Takasu N; Matsuda T; Ohta T; Tanaka Y; Ohshiro K; Mori N
Int J Cancer; 2006 Feb; 118(3):765-72. PubMed ID: 16106398
[TBL] [Abstract][Full Text] [Related]
37. A novel therapeutic molecule against HTLV-1 infection targeting provirus.
Tanaka A; Takeda S; Kariya R; Matsuda K; Urano E; Okada S; Komano J
Leukemia; 2013 Aug; 27(8):1621-7. PubMed ID: 23411465
[TBL] [Abstract][Full Text] [Related]
38. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
Ramadoss M; Mahadevan V
Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
[TBL] [Abstract][Full Text] [Related]
40. Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4.
Schulze J; Moosmayer D; Weiske J; Fernández-Montalván A; Herbst C; Jung M; Haendler B; Bader B
J Biomol Screen; 2015 Feb; 20(2):180-9. PubMed ID: 25266565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
